ResearcherRosalind Franklin University of Medicine and ScienceNo recent work listed

Hemantkumar S. Deokar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9603-4998; OpenAlex author ID A5022872903. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2018: 2 papers

Papers 2

QSAR Studies of New Pyrido[3,4-b]indole Derivatives as Inhibitors of Colon and Pancreatic Cancer Cell Proliferation. Co-author DOI 10.1007/s00044-018-2250-5 ↗
Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. Co-author DOI 10.3389/fphar.2018.00005 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

John K Buolamwini · 2 shared papers, 2018 · strength 0.20
- Paper QSAR Studies of New Pyrido[3,4-b]indole Derivatives as Inhibitors of Colon and Pancreatic Cancer Cell Proliferation. DOI 10.1007/s00044-018-2250-5 ↗
- Paper Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. DOI 10.3389/fphar.2018.00005 ↗
Ruiwen Zhang · 2 shared papers, 2018 · strength 0.20
- Paper QSAR Studies of New Pyrido[3,4-b]indole Derivatives as Inhibitors of Colon and Pancreatic Cancer Cell Proliferation. DOI 10.1007/s00044-018-2250-5 ↗
- Paper Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. DOI 10.3389/fphar.2018.00005 ↗
Jiang‐Jiang Qin · 1 shared paper, 2018 · strength 0.10
- Paper Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. DOI 10.3389/fphar.2018.00005 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.